Last updated: April 24, 2026
What does CA2716994 cover?
CA2716994 is a Canadian patent publication granted from the PCT route (family includes WO filings). The patent is classified under the pharmaceutical domain, covering drug-related subject matter and claiming specific chemical and/or pharmaceutical composition(s) and related use(s).
Scope at a practical level
- Claim coverage is anchored to defined molecular/structural subject matter (the “active” and/or “pharmaceutical composition” compositions).
- Protection extends to specific formulations and/or therapeutic uses as recited in the dependent and independent claim structure.
- Enforcement in Canada turns on claim construction under Canadian law: literal infringement requires practicing the claimed drug entity/formulation/use, while doctrine-like scope (for equivalents) applies through Canadian jurisprudence on purposive construction.
Core scope categories typically present in this family type
- Product claims: compound(s) and/or composition(s) comprising compound(s).
- Composition claims: pharmaceutical formulations with defined excipients or dosage forms.
- Method of treatment claims: therapeutic use claims for defined indications.
- Use/kit claims (if present): packaged administration frameworks or use instructions.
What does the claims set likely look like?
The claims in CA2716994 follow a standard Canadian pharmaceutical patent architecture: broad independent claims tied to the inventive concept, with narrowing dependent claims specifying subsets of compounds, formulation parameters, and/or indications.
Typical independent claim structure
- Independent compound claim
- Covers a defined compound or set of compounds by structural definition (or Markush-type definitions if used in the family).
- Independent pharmaceutical composition claim
- Covers a pharmaceutical composition comprising the defined compound(s) plus one or more formulation ingredients.
- Independent method/use claim
- Covers use of the compound(s) in a therapeutic method for a specified indication and/or patient population.
Typical dependent claim structure
- Specifies dosage form (tablet, capsule, solution, etc.), dosage range, route (oral, IV, etc.), and treatment regimen.
- Narrows indication subtypes, patient characteristics, or endpoints.
- Adds dependent composition limitations (excipient lists, concentration ranges, pH, stability constraints), if recited.
What is the legal scope of protection in Canada?
In Canada, the relevant scope is claim-defined. Patent infringement hinges on:
- Purposive construction of claim terms.
- Whether the accused product or use practices each feature of an asserted claim.
- Whether the claim is enabled and supports the breadth sought.
For drug patents, enforceable scope often concentrates on:
- Active ingredient coverage (compound/entity claims).
- Formulation coverage (composition claims).
- Indication coverage (method/use claims).
Where does CA2716994 sit in the patent landscape?
A meaningful landscape read depends on mapping:
- Family members (WO/EP/US/CN filings)
- Canadian priority date and PCT date
- Key forward citation paths (continuations, improvement patents)
- Early risks: generic entry triggers, second-generation reformulations, and indication expansions
For CA2716994, the landscape must be read through the lens of Canadian regulatory linkage to patents listed under Canada’s Patent Register (NOC / NDS linkage) and through family continuations that often show up as:
- Salt/polymorph follow-ons
- Alternate formulations
- Expanded indications
- Combination therapies
Landscape categories
- Primary family patent (CA2716994)
- Defines the original inventive chemical/composition/use scope.
- Second-generation Canadian filings
- Reformulations, polymorphs, salts, dosing regimens, and expanded indications, if the family continued.
- Combination strategy patents
- If the indication requires combination therapy, additional coverage may exist across companion patents.
Key risks to claim strength in Canada
Even when the claim set is broad, pharmaceutical patents in Canada face predictable risk points:
- Anticipation / obviousness
- If earlier art discloses the claimed compounds or close structural analogs, CA2716994’s breadth can be attacked.
- Insufficient disclosure
- If the description does not enable the full claimed genus (if Markush-like breadth exists), validity is challenged.
- Overbreadth (claim-defining vs. support)
- If claim coverage exceeds what is supported by experimental data in the disclosure, the claim set can be narrowed or invalidated.
- Use-claim vulnerabilities
- Method-of-treatment claims can be challenged for clarity and support of therapeutic indication boundaries.
Competitive impact: how CA2716994 affects generics and biosimilar-like entry (small molecule)
For small-molecule drugs, CA2716994 can shape generic entry in Canada through:
- Patent list blocking for linked NOC pathways, if listed for the reference product’s medicinal ingredient(s).
- Infringement litigation leverage: the generic must either launch “at risk,” negotiate a settlement, or pursue non-infringement/invalidity positions.
- Design-around pressure: generics often attempt to avoid literal claim coverage by changing:
- the compound/entity,
- the formulation composition,
- the claimed dose/route regimen,
- the claimed indication wording, where applicable.
Practical evaluation logic
- Literal infringement: does the generic’s product or proposed use contain all required claimed features?
- Claim narrowing: can the patentee’s construction be restricted by the specification and prosecution history?
- Validity defenses: anticipation, obviousness, enablement, and overbreadth.
What are the likely claim “pressure points” for enforcement?
For CA2716994’s landscape posture, the key enforcement pressure points typically align to:
- Compound definition tightness
- Overly broad genus claims are more vulnerable.
- Formulation parameter specificity
- If composition claims are broad (e.g., generic “pharmaceutical composition”), validity and enablement can be attacked, but enforcement can still be strong if the accused product matches the composition constraints.
- Indication language
- Indication claims can be easier to design around if the claim recites a narrow disease state or a specific patient subset.
- Combination coverage
- If the claim set includes combination therapy, the scope may depend on whether the accused regimen matches the defined components and therapeutic timing, if recited.
How to read CA2716994 in the broader Canadian patent map
A robust Canadian landscape view usually includes these layers:
- Upstream chemical patent layer
- Covers the core scaffold and general medicinal use.
- Downstream formulation layer
- Covers salts, polymorphs, particle size, excipients, controlled release, and dose.
- Clinical evidence layer
- Supports method-of-treatment and dosage ranges.
- Regulatory linkage layer
- Shows whether the patent is listed against the NDS for the relevant drug.
What’s the landscape deliverable: where CA2716994 sits and what to watch
Given CA2716994 is a Canadian patent with a defined claim set, the watchlist for a competitor or investor typically includes:
- Any Canadian continuations in the same family: additional claim sets with tighter composition or broader indications.
- Any late amendments or claim interpretation events (if available in file wrappers or post-grant disputes).
- Any new patents from the same assignee that target:
- alternative formulations,
- dosing regimens,
- new combination partners,
- expanded therapeutic indications.
Evidence table: landscape components to map (using CA2716994)
| Landscape element |
What to extract from the record |
Why it matters |
| Priority / filing dates |
Earliest priority date and Canadian filing/publication dates |
Determines term, prior art cutoff, and family relevance |
| Claim categories |
Compound, composition, and method/use independent claims |
Defines infringement pathways and design-around routes |
| Dependent narrowing |
Dosage form, dose, route, excipient constraints, indication subsets |
Identifies where infringement is easiest vs. hardest |
| Family members |
WO/EP/US/other filings tied to the same priority |
Shows whether broader protection exists outside Canada and whether Canada is “core” or “narrow” |
| Patent listing status |
Whether CA2716994 is listed for the relevant DIN/NOC linkage |
Determines regulatory blocking leverage |
| Forward improvement filings |
Later patents from same assignee using same scaffold |
Shows product lifecycle strategy and likely next litigation targets |
Key takeaways
- CA2716994’s scope is claim-defined and typically spans compound and pharmaceutical composition protection, with possible method-of-treatment and use claims.
- Enforcement in Canada depends on literal claim feature matching (plus Canadian claim construction rules) across product composition and/or prescribed use.
- The patent’s position within its family and any Canadian forward improvement filings are the primary indicators of whether the protection is durable or likely to be narrowed in practice.
- Competitor strategy for entry typically targets design-around routes: alternate compounds, alternate formulations, and/or non-implicating indication language where claims permit.
FAQs
1) What determines infringement risk from CA2716994 in Canada?
Infringement risk is driven by whether the accused product (compound and formulation) and/or the accused therapeutic use practices all elements of the asserted claims under Canadian claim construction.
2) Does CA2716994 likely protect only the active ingredient?
Typically no. Pharmaceutical patent families that include composition and method claims usually cover compound entities, pharmaceutical compositions, and sometimes therapeutic uses depending on the claim set.
3) How does CA2716994 affect generic entry timing?
If listed under Canada’s patent linkage regime for the reference product, it can create a regulatory blocking and litigation timeline. The precise effect depends on whether the specific claims are listed for the medicinal ingredient and formulation.
4) What is the biggest vulnerability for a pharma patent like CA2716994?
Common vulnerabilities are anticipation/obviousness, insufficient disclosure/enablement, and overbreadth relative to what the specification supports.
5) What patents should be checked next in the landscape?
Search for family continuations and forward improvement patents in Canada targeting salts/polymorphs, formulations, dosage regimens, expanded indications, and combination therapies.
References (APA)
[1] Canadian Intellectual Property Office (CIPO). Canada patent publication record for CA2716994.
[2] World Intellectual Property Organization (WIPO). WO-family records corresponding to the priority underlying CA2716994.
[3] Government of Canada. Regulations and framework for patent listing in the Patent Register under the NOC pathway (linkage regime).
